HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dermocosmetic Market Ripens With Uptake Of OTC Drug Ingredients

This article was originally published in The Tan Sheet

Executive Summary

The market for specialized dermocosmetics expands rapidly as personal marketers join the fray with products containing OTC drug ingredients for hair and skin care, says Euromonitor Beauty & Personal Care analyst Nicholas Micallef. Coal tar, ketoconazole and salicylic acid are among drug ingredients increasingly making their way into the space.

You may also be interested in...



Dermatology, Nasal Sprays Among Emerging OTC Switch Categories

FDA threw the switch floodgates open with the NSURE initiative and it has fueled interest with the recent first-in-class switches of Nasacort and Oxytrol for Women. Likely categories for successful switches include dermatology, nasal sprays in allergy, sleep, migraine relief and cholesterol management.

Elizabeth Arden Goes Pro With TPF 50, Sets “New Standard” In Sunscreen

Elizabeth Arden ventures into pro skin-care with its Triple Protection Factor Broad Spectrum Sunscreen SPF 50+, which will be available in physicians’ offices, along with other Elizabeth Arden RX products, in April. Combining SPF with an Antioxidant Complex and DNA Enzyme Complex, TPF 50 is being touted as “the most effective topical skin protection on the market.”

P&G Restores Volume Growth In Beauty, Grooming After Pricing Run

Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS123908

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel